Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2021 Aug;107(16):1296-1302.
doi: 10.1136/heartjnl-2020-318676. Epub 2021 May 5.

Quality of life and healthcare utilisation improvements after atrial fibrillation ablation

Dhiraj Gupta  1 , Johan Vijgen  2 , Tom De Potter  3 , Daniel Scherr  4 , Hugo Van Herendael  5 , Sebastien Knecht  6 , Richard Kobza  7 , Benjamin Berte  7 , Niels Sandgaard  8 , Jean-Paul Albenque  9 , Gábor Széplaki  10 , Yorick Stevenhagen  11 , Philippe Taghji  12 , Matt Wright  13 , Mattias Duytschaever  6
Affiliations
Clinical Trial

Quality of life and healthcare utilisation improvements after atrial fibrillation ablation

Dhiraj Gupta et al. Heart. 2021 Aug.

Abstract

Objective: Pulmonary vein isolation (PVI) guided by a standardised CLOSE (contiguous optimised lesions) protocol has been shown to increase clinical success after catheter ablation for paroxysmal atrial fibrillation (PAF). This study analysed healthcare utilisation and quality of life (QOL) outcomes from a large multicentre prospective study, measured association between QOL and atrial fibrillation (AF) burden and identified factors associated with lack of QOL improvement.

Methods: CLOSE-guided ablation was performed in 329 consecutive patients (age 61.4 years, 60.8% male) with drug-refractory PAF in 17 European centres. QOL was measured at baseline and 12 months post-ablation via Atrial Fibrillation Effect on QualiTy of Life Survey (AFEQT) and EuroQoL EQ-5D-5L questionnaires. All-cause and cardiovascular hospitalisations and cardioversions over 12 months pre-ablation and post-ablation were recorded. Rhythm monitoring included weekly and symptom-driven trans-telephonic monitoring, plus ECG and Holter monitoring at 3, 6 and 12 months. AF burden was defined as the percentage of postblanking tracings with an atrial tachyarrhythmia ≥30 s. Continuous measures across multiple time points were analysed using paired t-tests, and associations between various continuous measures were analysed using independent sample t-tests. Each statistical test used two-sided p values with a significance level of 0.05.

Results: Both QOL instruments showed significant 12-month improvements across all domains: AFEQT score increased 25.1-37.5 points and 33.3%-50.8% fewer patients reporting any problem across EuroQoL EQ-5D-5L domains. Overall, AFEQT improvement was highly associated with AF burden (p=0.009 for <10% vs ≥10% burden, p<0.001 for <20% vs ≥20% burden). Cardiovascular hospitalisations were significantly decreased after ablation (42%, p=0.001). Patients without substantial improvement in AFEQT (55/301, 18.2%) had higher AFEQT and CHA2DS2-VASc scores at baseline, and higher AF burden following PVI.

Conclusions: QOL improved and healthcare utilisation decreased significantly after ablation with a standardised CLOSE protocol. QOL improvement was significantly associated with impairment at baseline and AF burden after ablation.

Trial registration number: NCT03062046.

Keywords: atrial fibrillation; catheter ablation.

PubMed Disclaimer

Conflict of interest statement

Competing interests: Dr MD reports personal fees (consulting) from Biosense Webster, outside the submitted work; reports non-financial (travel) support for the submitted work. Dr RK reports grants from Biosense Webster, grants from Biotronik, grants from Abbott, grants from Medtronic, grants from Boston, grants from SIS Medical, outside the submitted work. Dr GS reports grants from Biosense Webster, during the conduct of the study; personal fees from Biosense Webster, personal fees from Abbott, outside the submitted work. Dr J-PA reports personal fees (consulting) from Biosense Webster and from Abbott outside the submitted work. Drs BB, TDP, SK, NS, DS, YS, PT, HVH, JV and MW have nothing to disclose.

Figures

Figure 1
Figure 1
Change in mean Atrial Fibrillation Effect on QualiTy of Life Survey (AFEQT) scores from baseline to 12 months postprocedure. All score improvements are statistically significant (p<0.001). AF, atrial fibrillation.
Figure 2
Figure 2
EuroQoL EQ-5D-5L change in percentage of patients with problems. Patients with problems include those reporting ‘slight’ or worse level of problem versus ‘none’. All decreases were statistically significant (p<0.001) except the self-care domain.
Figure 3
Figure 3
Change from baseline in 12-month overall Atrial Fibrillation Effect on QualiTy of Life Survey (AFEQT) score by atrial fibrillation (AF) burden level. (A) Change in overall AFEQT score by residual AF burden <10% or ≥10%. (B) Change in overall AFEQT score by residual AF burden <10% or ≥20% AF burden is defined as the percentage of recording days with an episode of atrial fibrillation, atrial tachycardia and/or atrial flutter lasting ≥30 s.
Figure 4
Figure 4
Changes in quality of life by post-ablation healthcare utilisation. (A) Change in overall Atrial Fibrillation Effect on QualiTy of Life Survey (AFEQT) score by re-ablation status. (B) Change in overall AFEQT score by cardioversion postblanking.
Figure 5
Figure 5
Atrial Fibrillation Effect on Quality of Life Survey (AFEQT) change versus baseline score.
Figure 6
Figure 6
Changes in 12-month all-cause and cardiovascular hospitalisations. Reductions in cardiovascular hospitalisations are statistically significant (p=0.001 for number of admissions, p=0.004 for number of patients with admissions).
See this image and copyright information in PMC

References

    1. Parmar BR, Jarrett TR, Kholmovski EG, et al. . Poor scar formation after ablation is associated with atrial fibrillation recurrence. J Interv Card Electrophysiol 2015;44:247–56. 10.1007/s10840-015-0060-y - DOI - PMC - PubMed
    1. Ariyarathna N, Kumar S, Thomas SP, et al. . Role of contact force sensing in catheter ablation of cardiac arrhythmias: evolution or history repeating itself? JACC Clin Electrophysiol 2018;4:707–23. 10.1016/j.jacep.2018.03.014 - DOI - PubMed
    1. Taghji P, El Haddad M, Phlips T, et al. . Evaluation of a strategy aiming to enclose the pulmonary veins with contiguous and optimized radiofrequency lesions in paroxysmal atrial fibrillation: a pilot study. JACC Clin Electrophysiol 2018;4:99–108. 10.1016/j.jacep.2017.06.023 - DOI - PubMed
    1. Phlips T, Taghji P, El Haddad M, et al. . Improving procedural and one-year outcome after contact force-guided pulmonary vein isolation: the role of interlesion distance, ablation index, and contact force variability in the 'CLOSE'-protocol. Europace 2018;20:f419–27. 10.1093/europace/eux376 - DOI - PubMed
    1. Duytschaever M, Vijgen J, De Potter T, et al. . Standardized pulmonary vein isolation workflow to enclose veins with contiguous lesions: the multicenter VISTAX trial. Europace. In Press 2020. - PubMed

Publication types

MeSH terms

Associated data